Pharma's Market
SPECIAL REPORT
MOST SHARED
- We're Not Greece: Italian Prime Minister Monti
- Obama Likely to Call for Cutting Top Corporate Tax Rate
- To Play Senate Cybersecurity Bill, Cramer Likes Fortinet Stock
- Greek Cabinet Approves EU, IMF Bailout Bill
- Special Feature: Wall Street History - How Wall Street Got Its Name
- How to Trade the Turmoil in Greece
- Private Homebuilders: Dead Men Walking
- Why Cramer Likes Select Comfort Over Tempur-pedic Stock
- Cramer: 10 Earnings to Watch Next Week
- Lightning Round: Trina Solar, Zoltek, Affymax and More
- In Search of America's ‘Hottest Forecasters’
- Dow vs. S&P 500: Which is a Better Investment?
- Mick Fleetwood on the MP3 ‘Dumbing Down’ of Music
- Avis on the Road to Strong Growth: Analyst
- Private Homebuilders: Dead Men Walking
- LinkedIn’s Growth Is Already Priced In: Analyst
- The Real Reason Behind Bank of America’s Rally
- 5 Hedge Funds’ Top Stocks Soar After 2011 Rout
- This Valentine’s Day Love Is Served on a Silver Platter
- Greek Cabinet Approves EU, IMF Bailout Bill
- We're Not Greece: Italian Prime Minister Monti
- Private Homebuilders in the US: Dead Men Walking
- Dividend Payout Could Hit Record Amount This Year
- With Investors So Bullish, Stock Pullback Must Be Ahead
- Obama Likely to Call for Cutting Top Corporate Tax Rate
- New York Fashion Week Fall 2012
- NetNet: Why Saving Greece Could Destroy the World
- My Funny Valentine: When Love and the Fed Collide
RSS FEED
Schering-Plough And ENHANCE: What Did They Know And When?
Text Size 
Reporter
 |
CNBC.com |
SGP [SGP
Loading...
()
] and Merck [MRK
Loading...
()
] are joint-venture partners on the pill which is a combination of Zocor and Zetia. Critics have alleged officials may have delayed releasing what many perceive as the negative results of the clinical trial.
You can see the filing for yourself here, but this is the lowdown:
SGP says Chairman and CEO Fred Hassan was told about the results on January 10th at 8 a.m. by Tom Koestler, the head of SGP's Research Institute. According to the filing, an executive VP was told at the exact same time, another exec veep learned about it half an hour later, and yet another EVP half an hour after that. Koestler was the first top-level guy to get the results on Jan. 7th at 2 p.m. The companies publicly released the results on January 14th at 8:05 a.m. ET according to the time stamp on the wire services we subscribe to at CNBC.
The filing also explains why SGP is reporting earnings much later than Merck this quarter. Recently I blogged that this is the first time in recent memory that the partners didn't come out on the same day.
The company says the later than usual date, Feb. 12th, is "to allow time to properly prepare consolidated financial results reflecting technical 'purchase accounting' adjustments for the November 2007 acquisition of Organon BioSciences N.V."
The filing also mentions that "the integration (with Organon) is progressing well."
*ENHANCE is the acronym for the study that compared Merck and Schering's cholesterol fighter Vytorin (a combo of Zocor and Zetia) to Zocor--which is now available as a generic--alone.
UPDATE: Interesting political/pharmaceutical factoid my producer, Ruth, just came across on the Associated Press wire. In a story about John McCain's health, it mentions that he's taking Vytorin.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes
